`Millions
`
`$500
`
`$450
`
`$400
`
`$350
`
`$300
`
`$250
`
`$200
`
`$150
`
`$100
`
`$50
`
`$0 -\------- --
`- - -~ ;;__---- - - - - -~ - -~
`- - -- - - - - - - - - -~ - - - - - - - - -~ - -~~ - --
`2002
`2003
`2004
`2005
`2006
`2007
`2008
`2009
`2010
`2011
`2012
`2013
`2014
`2015
`2016
`2017
`2018
`
`.-.-. Basaglar Franchise
`
`.-.-. Lantus Franchise
`
`.-.-. Levemir Franchise
`
`.-.-. Toujeo Franchise
`
`.-.-. Tresiba Franchise
`
`Source: IMS Health
`Note: Marketing is the sum of PROMOTIONS DOLLARS EXC SAMPLES and SAMPLES DOLLARS. PROMOTIONS DOLLARS EXC SAMPLES data span June 2002 through
`September 2017. SAMPLES DOLLARS data span January 2007 through November 2017. The long-acting category includes drugs listed under the IMS USC5 codes 39123 (Human
`Insulins Long Acting), 39133 (Analogs of Human Insulin Long Acting), and 39135 (Analogs of Human Insulin Ultra Long Acting). The Basaglar franchise consists of drugs listed as
`"Basaglar'' and "Basaglar KwikPen." The Lantus franchise consists of drugs listed as "Lantus," "Insulin Glargine," and "Lantus SoloSTAR." Marketing data are unavailable for Lantus
`OptiClik. The Levemir franchise consists of drugs listed as "Levemir," "Insulin Detemir," "Levemir FlexPen," and "Levemir FlexTouch." The Toujeo franchise consists of drugs listed as
`"Toujeo," "Toujeo SoloSTAR," and "Toujeo Max SoloSTAR ." The Tresiba franchise consists of drugs listed as "Tresiba," "Insulin Degludec," and "Tresiba FlexTouch."
`
`Sanofi Exhibit 2203.001
`Mylan v. Sanofi
`IPR2018-01675
`
`